Exploring the Therapeutic Potential of Medicinal Cannabis in Multiple Sclerosis

• Autor(a) principal: Pereira Levada, Leonardo
• Data de Publicação: 2024
• Outros Autores: Morgado Costa, Ana Luiza, Paiva, Pedro, Ferro Radicchi, Leonardo, Cavalcante Ribeiro, Jeferson, Della Torre Soler, João Vitor, de Oliveira Lemes, Maria Clara, Castelo Branco Pupe, Camila
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• DOI: 10.36557/2674-8169.2024v6n4p190-214
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1788
• topic: Esclerose múltipla; cannabis medicinal; tratamento

The medicinal use of cannabis dates back to various ancient societies with diverse objectives, such as pain and anxiety control. Despite contemporary prejudice against the recreational use of cannabis and its derivatives, they are among the most studied medications today, especially in the treatment of refractory neurological conditions like Multiple Sclerosis (MS). The review encompassed recent studies on the use of medicinal cannabis in the treatment of MS, highlighting different cannabinoids and their effectiveness in symptoms such as spasticity, central pain, urinary dysfunction, and sleep quality. While some cannabinoids have shown significant benefits in studies, such as nabiximols and THC/CBD in oromucosal spray, the efficacy of smoked Cannabis Sativa remains uncertain. The review also emphasized challenges such as adverse effects, lack of crucial information in studies, and the emergence of VSN16R as a potential alternative. Studies on long-term effects yielded disparate results, underscoring the need for further research. Economic analysis addressed the issue of cost-effectiveness, highlighting the importance of considering not only clinical aspects but also financial impacts. From this review, it is concluded that there are improvements in MS symptoms, while also pointing out challenges and underscoring the importance of overcoming ethical, economic, and political barriers to advance research on medicinal cannabis.